Identification and construction of combinatory cancer hallmark-based gene signature sets to predict recurrence and chemotherapy benefit in stage II colorectal cancer

JAMA Oncology

Volumn 2, Issue 1, 2016, Pages 37-45

  Gao, Shanwu ^a,b   Tibiche, Chabane ^b,c   Zou, Jinfeng ^b   Zaman, Naif ^b   Trifiro, Mark ^a,d   O'Connor McCourt, Maureen ^b   Wang, Edwin ^b,c,e  

^a HONGHE UNIVERSITY   (China)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; FLUOROURACIL; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; CANCER STAGING; COLORECTAL NEOPLASMS; DECISION SUPPORT SYSTEM; DISEASE FREE SURVIVAL; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETICS; HUMAN; KAPLAN MEIER METHOD; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; FLUOROURACIL; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATIENT SELECTION; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84973467716     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.3413     Document Type: Article

References (42)

1. Black ER, Falzon L, Aronson N. Gene Expression Profiling for Predicting Outcomes in Stage II Colon Cancer. 2012. http://www.ncbi.nlm.nih.gov/books/NBK115808/. Accessed September 9, 2015.
2. Dotan E, Cohen SJ. Challenges in the management of stage II colon cancer. Semin Oncol. 2011;38(4):511-520.
3. Kelley RK, Venook AP. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer. 2011;10(2):73-80.
4. Meropol NJ. Ongoing challenge of stage II colon cancer. J Clin Oncol. 2011;29(25):3346-3348.
5. Vachani C, Giantonio B. Stage II colon cancer: To treat or not to treat? 2013. http://www.oncolink.org/types/article.cfm?c=124&id=9621.
6. Scottish Intercollegiate Guidelines Network. Diagnosis and management of colorectal cancer guidelines. 2011. http://www.sign.ac.uk/pdf/sign126.pdf. Accessed September 10, 2015.
7. ASCO Institute for Quality. ASCO Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer. http://www.instituteforquality.org/asco-recommendations-adjuvant-chemotherapy-stage-ii-colon-cancer. Accessed September 17, 2015.
8. National Comprehensive Cancer Network. NCCN Guidelines for Treatment of Cancer by Site: Colon/Rectal Cancer. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#site. Accessed September 17, 2015.
9. Fang SH, Efron JE, Berho ME, Wexner SD. Dilemma of stage II colon cancer and decision making for adjuvant chemotherapy. J AmColl Surg. 2014;219(5):1056-1069.
10. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ; Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020-2029.
11. O'Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29 (25):3381-3388.
12. Li J, Lenferink AE, Deng Y, et al. Identification of high-quality cancer prognostic markers and metastasis network modules. Nat Commun. 2010; 1:34.
13. Park YY, Lee SS, Lim JY, et al. Comparison of prognostic genomic predictors in colorectal cancer. PLoS One. 2013;8(4):e60778.
14. Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29(35):4611-4619.
15. Kopetz S, Tabernero J, Rosenberg R, et al. Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors. Oncologist. 2015;20(2):127-133.
16. Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2011;29(1):17-24.
17. Maak M, Simon I, Nitsche U, et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg. 2013;257(6):1053-1058.
18. Srivastava G, Renfro LA, Behrens RJ, et al. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients. Oncologist. 2014;19(5):492-497.
19. Venook AP, Niedzwiecki D, Lopatin M, et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013;31(14):1775-1781.
20. Birnbaum DJ, Laibe S, Ferrari A, et al; COL2 Project. Expression profiles in stage II colon cancer according to APC gene status. Transl Oncol. 2012; 5(2):72-76.
21. De Sousa E Melo F, Colak S, Buikhuisen J, et al. Methylation of cancer-stem-cell-associatedWnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell. 2011;9(5):476-485.
22. Jorissen RN, Gibbs P, Christie M, et al. Metastasis-associated gene expression changes predict poor outcomes in patients with Dukes stage B and C colorectal cancer. Clin Cancer Res. 2009;15 (24):7642-7651.
23. Kikuchi A, Ishikawa T, Mogushi K, et al. Identification of NUCKS1 as a colorectal cancer prognostic marker through integrated expression and copy number analysis. Int J Cancer. 2013;132 (10):2295-2302.
24. Marisa L, De Reynies A, Duval A, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013;10(5): e1001453.
25. Reid JF, Gariboldi M, Sokolova V, et al. Integrative approach for prioritizing cancer genes in sporadic colon cancer. Genes Chromosomes Cancer. 2009;48(11):953-962.
26. Sheffer M, Bacolod MD, Zuk O, et al. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A. 2009; 106(17):7131-7136.
27. Smith JJ, Deane NG, Wu F, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 2010;138(3):958-968.
28. Staub E, Groene J, Heinze M, et al. An expression module ofWIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types. J Mol Med (Berl). 2009;87(6): 633-644.
29. Sveen A, Agesen TH, Nesbakken A, Rognum TO, Lothe RA, Skotheim RI. Transcriptome instability in colorectal cancer identified by exon microarray analyses: associations with splicing factor expression levels and patient survival. Genome Med. 2011;3(5):32.
30. Tsukamoto S, Ishikawa T, Iida S, et al. Clinical significance of osteoprotegerin expression in human colorectal cancer. Clin Cancer Res. 2011;17 (8):2444-2450.
31. Chen DT, Hernandez JM, Shibata D, et al. Complementary strand microRNAs mediate acquisition ofmetastatic potential in colonic adenocarcinoma. J Gastrointest Surg. 2012;16(5): 905-912.
32. Cui Q, Ma Y, Jaramillo M, et al. A map of human cancer signaling. Mol Syst Biol. 2007;3:152.
33. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
34. Wang E, Zaman N, Mcgee S, Milanese JS, Masoudi-Nejad A, O'Connor-McCourtM. Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data. Semin Cancer Biol. 2015; 30:4-12.
35. Zaman N, Li L, Jaramillo ML, et al. Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets. Cell Rep. 2013;5(1): 216-223.
36. Wang E, Lenferink A, O'Connor-McCourt M. Cancer systems biology: exploring cancer-associated genes on cellular networks. Cell Mol Life Sci. 2007;64(14):1752-1762.
37. Wang E, Zou J, Zaman N, Beitel LK, Trifiro M, Paliouras M. Cancer systems biology in the genome sequencing era: part 1, dissecting and modeling of tumor clones and their networks. Semin Cancer Biol. 2013;23(4):279-285.
38. Wang E, Zou J, Zaman N, Beitel LK, Trifiro M, Paliouras M. Cancer systems biology in the genome sequencing era: part 2, evolutionary dynamics of tumor clonal networks and drug resistance. Semin Cancer Biol. 2013;23(4):286-292.
39. Snaebjornsson P, Coupe VM, Jonasson L, Meijer GA, Van Grieken NC, Jonasson JG. pT4 stage II and III colon cancers carry the worst prognosis in a nationwide survival analysis: Shepherd's local peritoneal involvement revisited. Int J Cancer. 2014; 135(2):467-478.
40. Swamy R. Histopathological reporting of pT4 tumour stage in colorectal carcinomas: dotting the 'i's and crossing the 't's. J Clin Pathol. 2010;63(2): 110-115.
41. Cardoso F, Piccart-GebhartM, Van't Veer L, Rutgers E; TRANSBIG Consortium. TheMINDACT trial: the first prospective clinical validation of a genomic tool. Mol Oncol. 2007;1(3):246-251.
42. Agendia. MammaPrint 70-gene Breast Cancer Recurrence Assay. http://www.agendia.com/healthcare-professionals/breast-cancer/mammaprint/. Accessed September 17, 2015.